Canada markets open in 3 hours 26 minutes

Gritstone bio, Inc. (GRTS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.4600+0.0400 (+1.65%)
At close: 04:00PM EDT
2.3800 -0.08 (-3.25%)
After hours: 05:00PM EDT

Gritstone bio, Inc.

5959 Horton Street
Suite 300
EmeryVille, CA 94608
United States
510 871 6100
https://gritstonebio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees201

Key Executives

NameTitlePayExercisedYear Born
Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.Co-Founder, Pres, CEO & Director904.66kN/A1967
Mr. Erin E. Jones M.S.Chief Operating Officer597.74kN/A1972
Dr. Karin Jooss Ph.D.Head of R&D658.03kN/A1965
Ms. Vassiliki EconomidesExec. VP & CFON/AN/A1981
Mr. James ChoChief Accounting OfficerN/AN/AN/A
Mr. Rahsaan W. Thompson J.D.Exec. VP & Gen. CounselN/AN/A1971
Ms. Stacy ProctorSr. VP & Head of PeopleN/AN/AN/A
Dr. Matthew HawrylukExec. VP & Chief Bus. OfficerN/AN/A1978
Mr. Vijay Yabannavar Ph.D.Exec. VP & Chief Technical Devel. OfficerN/AN/A1962
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Corporate Governance

Gritstone bio, Inc.’s ISS Governance QualityScore as of July 1, 2022 is 7. The pillar scores are Audit: 6; Board: 5; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.